Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Reverb Therapeutics
Canada
- Vancouver, British columbia
- 21/02/2025
- Seed
- $21,000,000
We develop bispecific antibodies that exploit the potential of the natural immune system. Our Amplify•R platform amplifies and redirects endogenous cytokine signaling instead of recombinant cytokines. We avoid issues such as systemic toxicity, immunogenicity and manufacturing concerns.
- Industry Biotechnology Research
- Website https://www.reverbtx.com/
- LinkedIn https://www.linkedin.com/company/reverbtx/
Related People
David de GraafCo Founder
United States -
Greater Boston
I have the immodest goal of believing I can change the underpinnings of research and development of pharmaceuticals in order to provide integrative, personalized patient care in all therapeutic areas. I think that leadership should provide vision and direction, but I also believe that everyone needs to contribute to filling in that vision in a collaborative and constructive environment. I believe that unique skills are undervalued in large organizations and can shine in smaller ones.
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)